Kenyans Set to Receive Mpox Vaccines by December

photo: Mpox Vaccine.

Vaccines to Arrive Amid Growing Concern

The Kenyan government announced that citizens will receive Mpox vaccines by December. Health Director-General Patrick Amoth revealed that Kenya will get 2 million doses from a Nordic manufacturer based in Denmark. This decision follows last week’s declaration by the World Health Organisation (WHO) and Africa Centres for Disease Control and Prevention (CDC), which identified Mpox as a public health emergency.

Prioritization of Vulnerable Groups

Amoth emphasized that the government will prioritize vulnerable groups, much like during the Covid-19 pandemic. He assured Kenyans that these groups will receive the vaccines first due to limited availability. “We will not vaccinate everyone because of the scarcity. Therefore, we will prioritize those who need the vaccine most,” Amoth explained.

Understanding Mpox and Its Threat

Mpox, previously known as monkeypox, spreads through contact with an infected person, contaminated items, or sexual contact. The virus, now known as strain clade 1b, shows increased transmissibility and poses a higher risk to the population. Amoth stated that the government plans to sequence the virus to determine its genetic composition, which will aid in addressing the threat more effectively.

Government Measures to Combat Mpox

To address the rising threat, the Kenyan government has implemented several measures. Authorities have heightened surveillance at every point of entry into the country. Additionally, the government has increased training for health workers, ensuring they can identify and diagnose the disease accurately.

Laboratory Testing Capabilities

Kenya now boasts four dedicated laboratories specifically for testing Mpox cases. Moreover, the government has 100 additional laboratories on standby if needed. This robust infrastructure ensures the country remains prepared to handle any potential outbreak.

Rapid Response Teams on Standby

The Ministry of Health reassured the public that rapid response teams stand ready to tackle any suspected cases of Mpox. These teams have already screened over 300,000 travelers and tested 29 suspected cases, all of which returned negative results. This proactive approach aims to prevent the spread of the disease within the country.

Collaborative Efforts with Partner Institutions

Health Cabinet Secretary Deborah Barasa highlighted ongoing collaborations between the Ministry of Health National Public Health Laboratories (NPHL) and partner institutions such as the Kenya Medical Research Institute (KEMRI). Together, they conduct thorough testing of suspected cases. Barasa stressed that these collaborations strengthen the country’s ability to manage and contain Mpox effectively.

County-Level Preparedness

Counties across Kenya have also activated their emergency response mechanisms. Currently, 25 County Emergency Operation Centers (EOCs) are active and providing coordinated efforts in case investigations and contact tracing. Each county has also activated its Rapid Response Teams (RRTs), ensuring a swift response to any emerging cases.

Public Reassurance and Vigilance

The Ministry of Health continues to reassure the public that Kenya is well-prepared to manage the threat of Mpox. With multiple layers of preparedness and response in place, including vaccine prioritization, enhanced surveillance, and extensive laboratory support, the country remains vigilant against the potential spread of this viral disease.

Next Steps in the Fight Against Mpox

Looking ahead, the government plans to continue monitoring the situation closely. Authorities will adjust their strategies as needed to protect the population. Kenyans can expect regular updates on the progress of vaccine distribution and other preventive measures.

In conclusion, the Kenyan government’s proactive approach to addressing the Mpox threat demonstrates its commitment to safeguarding public health. With vaccines set to arrive by December and a comprehensive strategy in place, Kenya is well-positioned to combat this emerging health challenge.